JPRN-UMIN000009858已完成未知
A multicenter, open-label, single-dose study to investigate the effects of the ABCC4 (MRP4) rs3765534 G>A polymorphism on the pharmacokinetics of ceftizoxime in East Asian population - The effects of the ABCC4 (MRP4) rs3765534 G>A polymorphism on the pharmacokinetics of ceftizoxime in East Asian population
Department of Clinical Pharmacology and Therapeutics, Oita University Faculty of Medicine0 个研究点目标入组 38 人开始时间: 2013年2月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 50years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)A subject with history of allergies including study drug or any other food and drug allergies (aspirin, antibiotics, etc.), or history of clinically significant allergies 2)A subject with clinical evidence or history of hepatic (including carrier of hepatitis virus), renal, gastrointestinal, respiratory (including asthma and COPD), endocrine, neurologic, immunologic, hematologic, oncologic, psychiatric, or cardiovascular disease 3)A subject who shows a positive reaction to any one of serology tests (hepatitis B surface antigen (HBsAg), Hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody). 4)A subject with a history of surgery (except simple appendectomy or repair of hernia) 5)A subject with history of drug abuse or positive urine drug screening test 6)A subject who has taken any prescribed medication or herbal compounds within 14 days prior to the study drug administration. In addition, a subject who has taken any over-the-counter drug or vitamin supplements within 7 days prior to the study drug administration (However, investigators can judge the subject, who has taken the medications during those periods above, eligible for the trial if all other conditions are satisfied.) 7)A subject who consumes more than 7 units of alcohol (140g) per week or unable to stop drinking throughout the study period 8)A smoker (except for whom quitted smoking prior to the drug administration for at least 3 months) 9)A subject who heavily takes caffeine or caffeine-containing products, grapefruit, grapefruit juice, grapefruit-containing products 10)A female subject who are pregnant or breast feeding 11)A female subject who does not agree to use routinely adequate contraception* from signing of informed consent throughout the duration of the study and for 30 days after the last dose of study drug despite having a childbearing potential and being sexually active with a non-sterilized male partner.
研究者
相似试验
进行中（未招募）
1 期
A Study of Nasal Glucagon in Children with Insulin Dependent Diabetessevere hypoglycemiaEUCTR2021-006088-61-Outside-EU/EEAEli Lilly and Company
未知
1 期
A single-center, open-label, single-dose study investigating the safety, tolerability, and pharmacokinetic properties of nalmefene 10 mg tablets in healthy Japanese male subjectsHealthy adult maleJPRN-jRCT2080223097Otsuka Pharmaceutical Co., Ltd.7
进行中（未招募）
1 期
Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients.Hypertension, Chronic Kidney Disease, Nephrotic SyndromeEUCTR2015-004445-10-Outside-EU/EEAovartis Pharmaceuticals12
进行中（未招募）
不适用
The purpose of this study is to evaluate blood levels of solifenacin succinate (the study drug) in children after taking a single oral dose.EUCTR2011-000250-28-GBAstellas Pharma Europe B.V.12
进行中（未招募）
1 期
The purpose of this study is to evaluate blood levels of solifenacin succinate (the study drug) in children after taking a single oral dose.EUCTR2011-000250-28-BEAstellas Pharma Europe B.V.12